Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Educational Report
  • Published:

Acute Leukemias

Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia

Abstract

We analyzed the long-term outcome of 4865 patients treated in Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia (ALL) of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Treatment was characterized by progressive intensification of systemic therapy and reduction of cranial radiotherapy. A progressive improvement of results with reduction of isolated central nervous system relapse rate was obtained. Ten-year event-free survival increased from 53% in Study 82 to 72% in Study 95, whereas survival improved from 64 to 82%. Since 1991, all patients were treated according to Berlin-Frankfurt-Muenster (BFM) ALL treatment strategy. In Study 91, reduced treatment intensity (25%) yielded inferior results, but intensification of maintenance with high-dose (HD)-L-asparaginase (randomized) allowed to compensate for this disadvantage; in high-risk patients (HR, 15%), substitution of intensive polychemotherapy blocks for conventional BFM backbone failed to improve results. A marked improvement of results was obtained in HR patients when conventional BFM therapy was intensified with three polychemotherapy blocks and double delayed intensification (Study 95). The introduction of minimal residual disease monitoring and evaluation of common randomized questions by AIEOP and BFM groups in the protocol AIEOP-BFM-ALL 2000 are expected to further ameliorate treatment of children with ALL.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Paolucci G, Masera G, Vecchi V, Marsoni S, Pession A, Zurlo MG, et al. ALL Steering committee of the AIEOP. Treating childhood acute lymphoblastic leukemia (ALL): summary of ten years’ experience in Italy. Med Pediatr Oncol 1989; 17: 83–91.

    Article  CAS  Google Scholar 

  2. Masera G, Conter V, Rizzari C, Aricò M, Pession A, Paolucci G et al. AIEOP non-B ALL trials. Int J Pediatr Hematol Oncol 1999; 62: 102–111.

    Google Scholar 

  3. Vecchi V, Aricò M, Basso G, Ceci A, Madon E, Mandelli F et al. Risk-directed therapy for childhood acute lymphoblastic leukemia: results of the AIEOP ‘82 Studies. Cancer 1993; 72: 2517–2524.

    Article  CAS  Google Scholar 

  4. Paolucci G, Vecchi V, Favre C, Miniero R, Madon E, Pession A et al. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Haematologica 2001; 86: 478–484.

    CAS  PubMed  Google Scholar 

  5. Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, et al. for the ‘ Associazione Italiana Ematologia Oncologia Pediatrica’ (AIEOP). Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in intermediate risk ALL children treated with BFM-based intensive chemotherapy. J Clin Oncol 1995; 13: 2497–2502.

    Article  CAS  Google Scholar 

  6. Conter V, Aricò M, Valsecchi MG, Rizzari C, testi A, Miniero R, et al. for the ‘Associazione Italiana Ematologia Oncologia Pediatrica’ (AIEOP). Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 Study. Haematologica 1998; 83: 791–799.

    CAS  PubMed  Google Scholar 

  7. Putti MC, Rondelli R, Cocito MG, Aricò M, Sainati L, Conter V et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 Studies. Blood 1998; 92: 795–801.

    CAS  PubMed  Google Scholar 

  8. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 7161–7167.

    Article  CAS  Google Scholar 

  9. Rizzari C, Valsecchi MG, Aricò M, Conter V, Testi A, Barisone E, et al. for the ‘Associazione Italiana Ematologia Oncologia Pediatrica’ (AIEOP). Effect of protracted high-dose L-asparaginase given as a second exposure in a BFM-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study. J Clin Oncol 2001; 19: 1297–1303.

    Article  CAS  Google Scholar 

  10. Aricò M, Conter V, Valsecchi MG, Rizzari C, Boccalatte MF, Barisone E et al. Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica 2005; 90: 1186–1191.

    PubMed  Google Scholar 

  11. Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F et al. Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol 2008; 26: 283–289.

    Article  Google Scholar 

  12. Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007; 369: 123–131.

    Article  CAS  Google Scholar 

  13. Conter V, Aricò M, Valsecchi MG, Basso G, Biondi A, Madon E et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 2000; 14: 2196–2204.

    Article  CAS  Google Scholar 

  14. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122–3133.

    CAS  PubMed  Google Scholar 

  15. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy Study ALL-BFM 83). Klin Pädiatr 1987; 199: 151–160.

    Article  CAS  Google Scholar 

  16. Conter V, Schrappe M, Aricò M, Reiter A, Rizzari C, Dördelmann M, et al. for the ‘Associazione Italiana Ematologia Oncologia Pediatrica’ (AIEOP) and the Berlin-Frankfurt-Münster (BFM. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol 1997; 15: 2786–2791.

    Article  CAS  Google Scholar 

  17. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL REZ BFM 85). A relapse Study of the BFM group. Blood 1991; 78: 1166–1172.

    CAS  PubMed  Google Scholar 

  18. Kalbfleisch JD, Prentice RL . Chapter 7. The Statistical Analysis of Failure Time Data, 1st edn John Wiley: New York, 1980, 163–188.

    Google Scholar 

  19. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95: 3310–3322.

    CAS  PubMed  Google Scholar 

  20. Rosso P, Terracini B, Fears TR, Jankovic M, Fossati Bellani F, Arrighini A et al. Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter Study in Italy. Int J Cancer 1994; 59: 451–456.

    Article  CAS  Google Scholar 

  21. Jankovic M, Brouwers P, Valsecchi MG, Van Veldhuizer A, Huisman J, Kamphuis R et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC International Study Group on psychosocial aspects of childhood cancer. Lancet 1994; 344: 224–227.

    Article  CAS  Google Scholar 

  22. Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME et al. Augmented Berlin-Frankfurt-Münster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 2222–2230.

    Article  CAS  Google Scholar 

  23. Aricò M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 2002; 100: 420–426.

    Article  Google Scholar 

  24. van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738.

    Article  CAS  Google Scholar 

  25. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P et al. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009; 23: 528–534.

    Article  CAS  Google Scholar 

  26. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771–782.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to all parents associations and charities, which continuously supported the clinical and research work. This study has been partly supported by grants from the Ministero Università Ricerca Scientifica e Tecnologica (MURST), Grant 9906152551-007, AIRC (MGV) and PRIN (GB).

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to V Conter.

Appendix

Appendix

The following institutions enrolled patients in AIEOP-ALL studies:

Ancona, Div. Pediatria (Dr P Pierani)

Bari, Clinica Pediatrica (Prof. D De Mattia, Dr N Santoro)

Bergamo, Div. Pediatria (Dr M Provenzi)

Bologna, Clinica Pediatrica (Prof. A Pession, Dr R Rondelli)

Brescia, Clinica Pediatrica (Dr F Porta)

Cagliari, Servizio Oncoematologia Pediatrica (Prof. PF Biddau, Dr R Mura)

Catania, Div. Oncoematologia Pediatrica (Prof G Schilirò, Dr L Lo Nigro)

Catanzaro, Div. Ematologia (Dr C Consarino)

Cosenza, U.O. Pediatria (Dr D Sperlì)

Firenze, Ospedale Meyer, Dip. Pediatria, U.O. Oncoematologia Pediatrica (Dr M Aricò, Dr A Lippi)

Genova, Ist ‘G.Gaslini’ (Dr G Dini, Dr C Micalizzi)

Milano, Clinica Pediatrica ‘De Marchi’ (Dr D Portaleone)

Milano, Divisione di Pediatria, Ospedale Niguarda, (Dr F Fedeli)

Modena, Clinica Pediatrica (Prof. P Paolucci)

Monza, Clinica Pediatrica (Prof. G Masera, Dr V Conter, Prof. A Biondi, Dr M Jankovic, Dr C Rizzari)

Napoli, Divisione di Oncoematologia Pediatrica, Ospedale Pausillipon (Dr V Poggi, Dr R Parasole)

Napoli, II Università, Dip. Pediatria, Servizio Autonomo Oncologia Pediatrica (Prof. MT Di Tullio, Prof. F Casale)

Padova, Clinica Pediatrica II (Prof. M Carli, Prof. C Messina)

Palermo, Clinica Pediatrica I ( Dr P D’Angelo)

Parma, Clinica Pediatrica (Dr G Izzi, Dr P Bertolini)

Pavia, Clinica Pediatrica (Prof. F Locatelli, Dr G Giorgiani, Dr M Zecca)

Perugia, Div. Oncoematologia Pediatrica, Ospedale Silvestrini (Prof. F Aversa)

Pesaro, Divisione di Pediatria (Dr L Felici)

Pesaro, Ematologia, Ospedale di Muraglia (Dr G Visani)

Pescara, Divisione di Pediatria (Dr P Di Bartolomeo)

Pisa, Clinica Pediatrica III (Dr C Favre)

Reggio Calabria, Div. Ematologia, Ospedali Riuniti (Prof. F Nobile, Dr M Comis)

Roma, Div. Ematologia Pediatrica, Osp. ‘Bambin Gesù’ (Dr G De Rossi, Dr M Luciani)

Roma, Cattedra Ematologia (Prof. R Foà, Dr AM Testi)

Roma, Clinica Pediatrica (Prof. M Castello)

Roma, Oncologia Pediatrica, Policlinico Gemelli (Prof. R Riccardi)

San Giovanni Rotondo, Div. Pediatria, Ospedale Casa Sollievo della Sofferenza (Dr S Ladogana)

Siena, Clinica Pediatrica (Prof. A Acquaviva)

Sassari, Clinica Pediatrica (Prof. D Gallisai, Dr C Cosmi)

Torino, Clinica Pediatrica (Prof. E Madon, Dr E Barisone)

Trieste, Clinica Pediatrica (Prof. P Tamaro, Dr. GA Zanazzo)

Varese, Clinica Pediatrica (Prof. L Nespoli)

Verona, Clinica Pediatrica (Dr P Marradi)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Conter, V., Aricò, M., Basso, G. et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 24, 255–264 (2010). https://doi.org/10.1038/leu.2009.250

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.250

Keywords

This article is cited by

Search

Quick links